Arbutus Biopharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Arbutus Biopharma (ABUS).

Price Target Range — 7 Quarters

Analyst Consensus — 4 Analysts

1S.Buy

3Buy

Consensus RatingBuy# Analysts4Avg. Consensus PT$6Upside to Avg. PT+29.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 14, 2025	Chardan Capital	Keay Nakae	Maintained	Buy	$5
Aug 11, 2025	Chardan Capital	Keay Nakae	Maintained	Buy	$5
Mar 28, 2025	Chardan Capital	Keay Nakae	Maintained	Buy	$5
Jan 21, 2025	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$5
Nov 20, 2024	Chardan Capital	Keay Nakae	PT Raise	Buy	$5→$5
Nov 18, 2024	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$5
Nov 7, 2024	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$5
Nov 6, 2024	Chardan Capital	Keay Nakae	PT Raise	Buy	$4→$5
Sep 5, 2024	Jefferies	Dennis Ding	PT Raise	Buy	$5→$7
Aug 2, 2024	JMP Securities	Roy Buchanan	PT Raise	Market Outperform	$4→$5
Jun 7, 2024	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$5
Jun 6, 2024	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$5
Jun 5, 2024	Chardan Capital	Keay Nakae	Maintained	Buy	$4
May 3, 2024	Chardan Capital	Keay Nakae	Maintained	Buy	$4
Apr 4, 2024	JMP Securities	Roy Buchanan	Maintained	Market Outperform	$4
Mar 1, 2024	Chardan Capital	Keay Nakae	Maintained	Buy	$4
Mar 1, 2024	HC Wainwright & Co.	Ed Arce	PT Cut	Buy	$6→$5

Analyst Ratings News

Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars

Moderna shares jump after a $950 million settlement over COVID-19 vaccine patents, easing investor concerns and clearing legal uncertainty.

Vandana Singh

PRO
Chardan Capital Maintains Buy on Arbutus Biopharma, Maintains $5 Price Target

Chardan Capital analyst Keay Nakae maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $5 price target.

Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on Arbutus Biopharma, Maintains $5 Price Target

Chardan Capital analyst Keay Nakae maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $5 price target.

Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on Arbutus Biopharma, Maintains $5 Price Target

Chardan Capital analyst Keay Nakae maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $5 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $5 Price Target

HC Wainwright & Co. analyst Ed Arce reiterates Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $5 price target.

Benzinga Newsdesk

Walmart To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday

Avi Kapoor

Arbutus Biopharma Corp

뉴스

파트너 / 기고자

벤징가 글로벌

Arbutus Biopharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars

PRO
Chardan Capital Maintains Buy on Arbutus Biopharma, Maintains $5 Price Target

PRO
Chardan Capital Maintains Buy on Arbutus Biopharma, Maintains $5 Price Target

PRO
Chardan Capital Maintains Buy on Arbutus Biopharma, Maintains $5 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $5 Price Target

Walmart To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday

People Also Watch

People Also Watch

Arbutus Biopharma Corp

뉴스

파트너 / 기고자

벤징가 글로벌

Arbutus Biopharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars

PROChardan Capital Maintains Buy on Arbutus Biopharma, Maintains $5 Price Target

PROChardan Capital Maintains Buy on Arbutus Biopharma, Maintains $5 Price Target

PROChardan Capital Maintains Buy on Arbutus Biopharma, Maintains $5 Price Target

PROHC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $5 Price Target

Walmart To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday

People Also Watch

People Also Watch

PRO
Chardan Capital Maintains Buy on Arbutus Biopharma, Maintains $5 Price Target

PRO
Chardan Capital Maintains Buy on Arbutus Biopharma, Maintains $5 Price Target

PRO
Chardan Capital Maintains Buy on Arbutus Biopharma, Maintains $5 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $5 Price Target